Tri-Lo-Sprintec Shortage: What Providers and Prescribers Need to Know in 2026

If your patients are calling about Tri-Lo-Sprintec 28 Day being out of stock, this guide gives you the clinical context and practical prescribing guidance you need. The situation is manageable — here's how to address it efficiently.

Current Shortage Status (2026)

As of 2026, norgestimate/ethinyl estradiol triphasic low-dose tablets are NOT listed on the FDA's official drug shortage database. National supply is stable across multiple generic manufacturers. The primary driver of patient complaints is pharmacy-level logistics and residual confusion from the voluntary discontinuation of brand-name Ortho Tri-Cyclen Lo by Janssen Pharmaceuticals.

Why Patients Are Having Trouble Filling Prescriptions

Several prescribing and dispensing patterns are contributing to patient access issues:

• Prescriptions written for discontinued brands: Ortho Tri-Cyclen Lo is no longer manufactured. Prescriptions still referencing this brand name create friction at the pharmacy.
• DAW notations: "Dispense as written" prevents pharmacist substitution to AB-rated equivalents, creating unnecessary delays.
• Single-pharmacy dependency: Patients loyal to one pharmacy may not know that an equivalent is in stock two miles away.
• Short supplies prescribed: 30-day supplies require monthly refills, increasing the chance of a lapse in supply.

Prescribing Recommendations to Maximize Patient Access

The following prescribing practices significantly reduce access issues for patients on Tri-Lo-Sprintec:

1. Write for the generic. Prescribe "norgestimate/ethinyl estradiol triphasic (low dose)" rather than a specific brand name. This gives pharmacies maximum flexibility to fill with any AB-rated equivalent in stock.
2. Remove DAW restrictions. Unless there is a clinically specific reason a patient must receive a particular manufacturer's product, avoid dispense-as-written notations.
3. Prescribe 90-day supplies. Reducing the frequency of refills is the simplest way to reduce access disruptions. Most insurance plans allow 90-day fills for oral contraceptives.
4. Counsel patients on equivalent generics. Inform patients that Tri-Lo-Estarylla, Tri-Lo-Mili, Tri-Lo-Marzia, and Tri-Vylibra Lo are therapeutically identical — so they don't panic when they see a different name on the box.

Therapeutic Alternatives When Norgestimate/EE Low-Dose Is Unavailable

In the rare event that no norgestimate/EE triphasic low-dose product is locally available, consider the following alternatives by clinical priority:

1. Triphasic norgestimate/EE standard-dose (Tri-Sprintec): Same progestin, 35 mcg EE (vs. 25 mcg). Clinically reasonable if patient is not estrogen-sensitive. Most straightforward therapeutic switch.
2. Monophasic norgestimate/EE (Sprintec): Same active ingredients, fixed dose (0.25 mg norgestimate/0.035 mg EE). Appropriate for patients with no history of triphasic-specific benefit.
3. Levonorgestrel/EE: Different progestin. Widely available, low cost. Appropriate for most patients without specific norgestimate requirement.
4. Drospirenone/EE: Consider for patients with PMDD, acne, or fluid retention concerns. Note different side-effect and interaction profile.

ACA Coverage and Patient Cost Considerations

Under the ACA contraceptive mandate, most commercial insurance plans are required to cover at least one norgestimate/EE triphasic generic at $0 cost-sharing. If a patient's plan covers only a specific brand name and that brand is unavailable, the plan may be required to cover the prescribed equivalent — advise patients to contact their insurer for an exception or coverage clarification.

medfinder partners with provider practices to help patients locate medications in stock. Learn more at medfinder for providers.

Also see: How to Help Your Patients Find Tri-Lo-Sprintec in Stock: A Provider's Guide.